Charles River Laboratories International Inc.

5 days ago · businesswire.com

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) has introduced rapid cell banking programs designed to significantly accelerate release timelines, enabling biopharmaceutical and advanced therapy developers to reach critical milestones faster and bring innovative treatments to patients sooner. By combining rapid cell bank and release packages with advanced characterization using Next-Generation Sequencing (NGS), Charles River delivers a comprehensiv.

6 days ago · seekingalpha.com

Charles River Laboratories International, Inc. (CRL) Presents at 2026 Global Healthcare Conference Transcript

8 days ago · seekingalpha.com

Charles River Laboratories International, Inc. (CRL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

18 days ago · zacks.com

Charles River (CRL) reported earnings 30 days ago. What's next for the stock?

21 days ago · zacks.com

Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.

1 month ago · zacks.com

Charles River's 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.

1 month ago · zacks.com

CRL's shares have surged 88.6% in a year as DSA returns to organic growth, bookings climb and new testing initiatives broaden its strategy.

1 month ago · defenseworld.net

Shares of Charles River Laboratories International, Inc. (NYSE: CRL - Get Free Report) hit a new 52-week high on Tuesday. The company traded as high as $277.07 and last traded at $276.34, with a volume of 1025310 shares trading hands. The stock had previously closed at $267.49. Analyst Ratings Changes CRL has been the subject

1 month ago · zacks.com

Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

2 months ago · marketbeat.com

Charles River Laboratories International NYSE: CRL reported second-quarter results that exceeded its prior outlook, citing improved demand in its Discovery and Safety Assessment, or DSA, business and stronger-than-expected manufacturing performance. The company raised its full-year revenue, earnings and free-cash-flow guidance while maintaining a cautious view that the recovery in biopharmaceutical demand will progress gradually.